Pentadecapeptide BPC 157: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.
Placebo: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.
Study summary
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
Eligibility
Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria:
* Age 18 to 45 years.
* Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
* MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.
* Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport.
* Willingness to follow the standardized rehabilitation protocol and attend all study visits.
* For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose.
Exclusion Criteria:
* Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.
* Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.
* Prior hamstring strain on the index limb within the past 6 months.
* Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening.
* Known bleeding disorder or current therapeutic anticoagulation.
* Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.
* Known allergy or hypersensitivity to components of the investigational product or placebo.
* Pregnant or breastfeeding.
* Current participation in another interventional clinical study or participation within 30 days prior to screening.
* Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority
Primary outcome measure(s)
Time to return to unrestricted sport participation (days) — 8 Weeks defined as clearance by a blinded sports medicine clinician and completion of a standardized functional performance battery without pain-limited stopping.
Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review. — 14 Days
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.